A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Identifier
MAF/AGN/OPH/GLA/034
CT.gov Identifier
NCT01589510
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.01% ophthalmic solution
    • Phase
    N/A
    Sex
    Female & Male
    Age
    16+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of POAG or OHT * Prescribed Lumigan® 0.01%
    Exclusion Criteria:
    * None

    Protocol Summary

    A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

    Study Locations

    Location
    Status
    Location
    Vienna, Austria
    Status
    Not applicable